William Blair research analyst Matt Phipps joined CNBC’s “Worldwide Exchange” to discuss the implications for pharmaceutical companies that have their drugs listed on Medicare’s price negotiation roster.
Equity Research
Matt Phipps Guests on CNBC
Delivered to Your Inbox
Stay up-to-date with the latest William Blair news and insights
Our Latest News
-
Aardvark Therapeutics, Inc.: Initiation of Research Coverage
William Blair initiated research coverage of Aardvark Therapeutics, Inc. (AARD $13.98). Aardvark is advancing ARD-101, an oral therapy that targets bitter taste receptors (TAS2Rs) in the gastrointestinal tract, and ARD-201, a combination of ARD-101 and a DPP-4 inhibitor, for treating Prader-Willi syndrome (PWS) and obesity, respectively.
-
-